SCHEDULE: Malone Wealth Ventures Discloses 19.4% Stake in Quantum Biopharma Ltd.

Malone Wealth Ventures LLC has filed an amended Schedule 13G, reporting a 19.4% beneficial ownership stake in Quantum Biopharma Ltd.'s common stock as of July 10, 2025.

Summary

• Malone Wealth Ventures LLC, an investment adviser, reported beneficial ownership of 735,148 shares of Quantum Biopharma Ltd. common stock.
• This ownership represents 19.4% of the total class of securities.
• Malone Wealth Ventures LLC holds sole voting power over 103,601 shares and sole dispositive power over 735,148 shares.
• The shares are certified to be acquired and held in the ordinary course of business, not for the purpose of changing or influencing control of Quantum Biopharma Ltd.
• Clients of Malone Wealth Ventures LLC have the right to receive dividends or proceeds from the sale of these securities, with no individual client known to hold more than 5% of the class.

Sentiment

Score: 7

Explanation: The filing indicates a significant, passive institutional investment, which is generally a positive sign of confidence in the company. However, it contains no operational or financial news about the company itself, so the sentiment is neutral to slightly positive based on the investor's continued holding.

Positives

• A significant institutional investor, Malone Wealth Ventures LLC, maintains a substantial stake (19.4%) in Quantum Biopharma Ltd., indicating continued confidence.
• The filing explicitly states that the shares are held for investment purposes in the ordinary course of business, not for hostile takeover or control-influencing activities, which can provide stability.

Risks

• This Schedule 13G filing is a disclosure of beneficial ownership and does not contain specific risks related to Quantum Biopharma Ltd.'s operational or financial performance.

Future Outlook

This Schedule 13G filing does not provide forward-looking statements or guidance regarding Quantum Biopharma Ltd.'s future operations or financial performance. It solely reports current beneficial ownership by an investment adviser.

Management Comments

• "The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11." (Certification by Kevin M Malone, President and CEO of Malone Wealth Ventures LLC)

Industry Context

This filing is a routine disclosure of a significant passive investment by an investment adviser in a biopharma company. It reflects an institutional investor's position rather than a strategic industry move or competitive development. The biopharma industry often sees such institutional holdings as part of diversified portfolios, indicating a belief in the long-term value of the sector or specific companies within it.

Comparison to Industry Standards

• As a Schedule 13G filing, this document primarily reports beneficial ownership and does not contain operational or financial results for direct comparison to industry standards.
• The 19.4% stake is a substantial passive investment, common for institutional investors in publicly traded companies, but its significance is relative to the company's market capitalization and liquidity.
• For example, similar large passive stakes are held by institutional investors in established biopharma companies like Amgen (e.g., by large asset managers such as Vanguard Group or BlackRock) or Gilead Sciences, though the specific percentages vary widely based on the investor's strategy, the company's size, and its public float.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, potentially signaling confidence in the company's long-term prospects.
• Management: Awareness of a large passive investor, but no direct impact on operations or strategy is implied by this filing, as the investment is stated to be for ordinary course purposes.

Next Steps

• Quantum Biopharma Ltd. will continue its regular SEC reporting obligations.
• Malone Wealth Ventures LLC will file future amendments to Schedule 13G if their beneficial ownership percentage changes by more than 1% or if they change their investment intent from passive to active.

Key Dates

Recommendation

Keywords

Quantum Biopharma Ltd., Malone Wealth Ventures LLC, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, SEC Filing, Biopharma, Institutional Ownership